“Acute Kidney Injury (AKI) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Acute Kidney Injury Market.
The Acute Kidney Injury Pipeline report embraces in-depth commercial, regulatory, and Acute Kidney Injury clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Acute Kidney Injury drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
The report provides insights into:
The report provides detailed insights into the emerging therapies for Acute Kidney Injury treatment and the aggregate therapies developed by major pharma companies.
It accesses the different Acute Kidney Injury therapies segmented into early-stage, mid-stage, and late-stage clinical development.
It outlines the major Acute Kidney Injury companies involved in targeted therapeutics development, with respective active and inactive (dormant or discontinued) projects.
The report evaluates the Acute Kidney Injury drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Acute Kidney Injury therapeutic market.
Acute Kidney Injury Therapeutics Landscape
For the past several years, it can be observed that the current treatment for AKI is mainly supportive in nature, and no therapeutic modalities to date have shown efficacy in treating the condition. Management of AKI depends on the use of off-label drugs, which includes various drug classes such as ACE inhibitors, angiotensin II-receptor blockers (ARBs), diuretics, nonsteroidal anti-inflammatory drugs (NSAIDs), along with renal replacement therapy (RRT).
A cornerstone of the management of all patients with AKI is to monitor urine output and initially monitor serum creatinine levels (SCr) several times a day. In addition, it is recommended to treat electrolyte disturbances, discontinue or dose-adjust nephrotoxic drugs, and dose-adjust drugs with renal elimination.
There are approx. 30+ key companies developing therapies for Acute Kidney Injury. Currently, GUARD THERAPEUTICS is leading the therapeutics market with its Acute Kidney Injury drug candidates in the most advanced stage of clinical development.
Robust pipeline with a novel mechanism of action and increasing incidence are major market drivers for the AKI market growth. Additionally, the AKI pipeline is also expected to change the current dynamics of the market, which presently comprises biologics and molecules with new mechanisms of action like RMC-035, OCE-205, bRESCAP, and others.
Acute Kidney Injury Companies Actively Working in the Therapeutic Market Include:
GUARD THERAPEUTICS, Rénibus Therapeutics, Sentien Biotechnologies, Angion Biomedica, Quark-Pharmaceuticals, AM-Pharma Holding, Metro International Biotech, LLC, MediBeacon, Arch Biopartners Inc., Ocelot Bio, Inc, Pharming Technologies B.V., Vifor Pharma, Mission Therapeutics, XORTX Therapeutics, Ampio Pharmaceuticals Inc., Sulfateq BV, Atorvia, EBI Exponential Biotherapies, Serpin Pharma, CalciMedica Inc., ILIAS Biologics Inc., Arch Biopartners Inc., and many others.
Emerging and Marketed Acute Kidney Injury Drugs Covered in the Report Include:
RMC-035: GUARD THERAPEUTICS
RBT-1: Rénibus Therapeutics
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Acute Kidney Injury Companies Working in the Market @
Analysis of Emerging Acute Kidney Injury Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued and inactive candidates
Route of Administration
Acute Kidney Injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Learn How the Acute Kidney Injury Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Acute Kidney Injury Treatment Patterns
4. Acute Kidney Injury – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Acute Kidney Injury Late Stage Products (Phase-III)
7. Acute Kidney Injury Mid-Stage Products (Phase-II)
8. Acute Kidney Injury Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Acute Kidney Injury Discontinued Products
13. Acute Kidney Injury Product Profiles
14. Major Acute Kidney Injury Companies in the Market
15. Key Products in the Acute Kidney Injury Therapeutics Segment
16. Dormant and Discontinued Products
17. Acute Kidney Injury Unmet Needs
18. Acute Kidney Injury Future Perspectives
19. Acute Kidney Injury Analyst Review
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
“Diabetes Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Diabetes market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Diabetes market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States